{"disease":{"id":"advanced-soft-tissue-sarcoma","name":"advanced soft tissue sarcoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT03138161","title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Sarcoma Oncology Research Center, LLC","has_results":false},{"nct_id":"NCT05146440","title":"Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":195,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT02500797","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04705818","title":"Combining Epigenetic And Immune Therapy to Beat Cancer.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05809830","title":"Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT03838744","title":"Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Italian Sarcoma Group","has_results":false},{"nct_id":"NCT01514188","title":"Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":true},{"nct_id":"NCT04239443","title":"Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT01975519","title":"A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"Tracon Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT06981637","title":"Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT05694871","title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":77,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06498648","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03022448","title":"Geriatric Assessmen of Elderly \"Unsuited\" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT02235701","title":"Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":true},{"nct_id":"NCT05836571","title":"Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute LAO","has_results":false},{"nct_id":"NCT04028063","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT06062927","title":"Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06367075","title":"A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":53,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07156643","title":"A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":46,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05722977","title":"Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05352750","title":"Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Sonnet BioTherapeutics","has_results":false},{"nct_id":"NCT05876715","title":"LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"ERLINDA M GORDON","has_results":false},{"nct_id":"NCT06644287","title":"The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03670069","title":"Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT05333458","title":"Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04204941","title":"Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT03526250","title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04619056","title":"First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"CEBIOTEX","has_results":false},{"nct_id":"NCT03213665","title":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03698994","title":"Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05620693","title":"Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Shenzhen University General Hospital","has_results":false},{"nct_id":"NCT07283731","title":"Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05941325","title":"A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Shanghai 6th People's Hospital","has_results":false},{"nct_id":"NCT03210714","title":"Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03660930","title":"Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03213678","title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03009201","title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04780464","title":"A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT05043649","title":"Camsirubicin + Pegfilgrastim to Determine MTD in ASTS","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Monopar Therapeutics","has_results":false},{"nct_id":"NCT03213652","title":"Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03213704","title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05154630","title":"Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT03727789","title":"CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03233204","title":"Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03220035","title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03698227","title":"OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}